Literature DB >> 7261836

Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.

J P Miguet, D Vuitton, J P Deschamps, H Allemand, C Joanne, P Bechtel, P Carayon.   

Abstract

The antipyrine metabolic clearance rate (MCR) was studied in two groups of patients with similar degrees of cholestasis and hepatic damage, but differing mechanisms of cholestasis. The plasma disappearance rate of antipyrine in 18 patients with extrahepatic cholestasis and 11 patients with intrahepatic cholestasis was compared with that of two groups of control subjects without liver disease who were matched for age. Whereas no significant difference was observed for the antipyrine MCR between patients with extrahepatic cholestasis and their controls [30.7 +/- 11.2 (SD) as against 31.6 +/- 10.0 ml/min], the antipyrine MCR was significantly lower (P less than 0.001) in the patients with intrahepatic cholestasis than in their controls (16.2 +/- 4.5 vs 37.4 +/- 17.3 ml/min). These results suggest that cholestasis per se does not change the rate of metabolism of drugs by the liver. The decrease of antipyrine MCR in patients with intrahepatic cholestasis could be due to a reduced functional parenchymal mass related to some degree of hepatic necrosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7261836     DOI: 10.1007/BF01316861

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

Authors:  E S Vesell; G T Passananti; P A Glenwright; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

2.  The endoplasmic reticulum of the rat liver cell in experimental mechanical cholestasis. Correlated biochemical and ultrastructural-morphometric studies on structure and enzyme composition.

Authors:  H Denk; R Eckerstorfer; H P Rohr
Journal:  Exp Mol Pathol       Date:  1977-04       Impact factor: 3.362

3.  The use of antipyrine in the measurement of total body water in man.

Authors:  R SOBERMAN; B B BRODIE
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

4.  Effect of acute viral hepatitis in man on the disposition and elimination of meperidine.

Authors:  T S McHorse; G R Wilkinson; R F Johnson; S Schenker
Journal:  Gastroenterology       Date:  1975-04       Impact factor: 22.682

5.  Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.

Authors:  G W Hepner; E S Vesell; A Lipton; H A Harvey; G R Wilkinson; S Schenker
Journal:  J Lab Clin Med       Date:  1977-09

6.  Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs.

Authors:  E S Vesell; C J Lee; G T Passananti; C A Shively
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

7.  Phenazone metabolism in patients with liver disease.

Authors:  P B Andreasen; G Greisen
Journal:  Eur J Clin Invest       Date:  1976-01-30       Impact factor: 4.686

Review 8.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Determinants of serum antipyrine half-lives in patients with liver disease.

Authors:  R A Branch; C M Herbert; A E Read
Journal:  Gut       Date:  1973-07       Impact factor: 23.059

10.  Spironolactone and enzyme induction in patients with alcoholic cirrhosis.

Authors:  J P Miguet; D Vuitton; A Thebault-Lucas; C Joanne; D Dhumeaux
Journal:  Gastroenterology       Date:  1980-05       Impact factor: 22.682

View more
  4 in total

Review 1.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

3.  Antipyrine clearance in patients with Gilbert's syndrome.

Authors:  T Ishizaki; K Chiba; T Sasaki
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis.

Authors:  J Cotting; T Zeugin; U Steiger; J Reichen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.